Publications

5900 Results

Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Lung and/or Liver Metastases (NCI/SWOG S1609)

Authors
Othus M;Wang Y;Chae YK;Davies M;Dietrich E;Patel SP;Kurzrock R
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 2633 poster
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Post-Treatment Recovery Patterns among Patients with Early-Stage Cancer who Develop Taxane-Induced Peripheral Neuropathy (TIPN): SWOG S1714 (NCT03939481)

Authors
Trivedi M;Unger JM;Hertz DL;Till C;Brannagan T;Smith S;Schneider BP;Irvin WJ;Hathaway AR;Vander Woude AC;Gudena VK;Cabrera-Galeana PA;Orsted M;LeBlanc ML;Fisch MJ;Henry NL;Hershman DL
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 12117 poster
Year
2026
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1714

Vitamin D insufficiency and risk of taxane-induced peripheral neuropathy: Results from SWOG S1714

Authors
Nguyen-Hoang N;Henry NL;Hershman DL;Trivedi MS;Hertz DL
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 12012 rapid oral
Year
2026
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1714

First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer

Authors
Nappi L;Colby S;Hamilton RW;Harzstark A;Adra N;Daneshmand S;Ryan CW;Eggener SE;Fung C;Johnson R;Lerner SP;Arnold KB;Arun B;Rae JM;Blanke CD;LeBlanc ML;Parulekar WR;Einhorn LH;Kollmannsberger CK;Nichols CR
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs LBA5003 oral; J Clin Oncol 44, 2026 (suppl 17; abstr LBA5003) DOI: 10.1200/JCO.2026.44.17_suppl.LBA5003
Year
2026
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S1823

Baseline Financial and Credit Status of Participants Enrolled in SWOG S1912CD

Authors
Shankaran V;Bell-Brown A;Darke A;Hopkins T;Watabayashi K;Unger JM;Dzingle S;Carlos R;Langer S;Hershman DL;Ramsey SD
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 11049 poster
Year
2026
Research Committee(s)
Cancer Care Delivery
Study Number(s)
S1912CD

Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2) Mutations: SWOG S2001

Authors
Chung V;Guthrie KA;Pishvaian MJ;Lowy AM;Sohal D;Colby S;Reiss KA;Khan G;Winograd R;Meyerhardt JA;O‘Reilly EM;Chiorean EG;Philip PA
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 4012 rapid oral
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
S2001

Associations between self-efficacy and symptom burden in young women with breast cancer initiating endocrine therapy (ET) on SWOG S2010

Authors
Henry NL;Darke A;Unger JM;Schott A;Kumar P;Mazo Canola M;Sathe C;Cabrera-Galeana P;Kengla A;Fisch MJ;Hershman DL
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 521 poster
Year
2026
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S2010

Immune Checkpoint Inhibitor (ICI) Toxicity in a Large Prospective Cohort of Patients with Solid Tumors: The I-CHECKIT Study (SWOG S2013)

Authors
Gunturu K;Unger JM;Hershman DL;Darke A;Kuderer N;Wei AZ;Hu-Lieskovan S;Walshauser M;Nabi J;Fisch MJ;Henry NL
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 2640 poster
Year
2026
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S2013

S2433: Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Authors
Safyan RA;Colby S;Singh H;Guthrie KA;Sun V;Wadlow R;Gbolahan OB;Sohal D;Lowy AM;Ahmad S;Chiorean EG;Philip PA
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs TPS4264 TIP poster
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
S2433

SWOG S2107: randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAFV600E metastatic colorectal cancer (mCRC)

Authors
Morris V;Colby S;Kopetz S;Guthrie KA;Chapin WJ;Breakstone R;Hu ZI;Fakih M;Gholami S;Gold PJ;Chiorean EG;Philip PA
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 3504 oral
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
S2107